If you are battling kidney cancer, otherwise known as renal cell carcinoma (RCC), The DART Study may be the next treatment option for you to consider. Dalantercept, in combination with axitinib, an FDA approved therapy, aims to halt the growth and spread of RCC.
The DART Study is testing the safety and efficacy of dalantercept in combination with axitinib and is now enrolling patients with RCC nationwide.
Eligible participants must have:
- A diagnosis of advanced renal cell carcinoma (RCC)
- Received treatment with only one VEGF-pathway inhibitor such as sunitinib (Sutent), pazopanib (Votrient), bevacizumab (Avastin), sorafenib (Nexavar), cabozantinib (Cometriq), or tivozanib
Other prior therapies permitted but not required for participation include:
- Either everolimus (Afinitor) or temsirolimus (Torisel)
- Immunotherapy (therapies targeting the immune system)
Contact us today to see if you qualify:
What is The DART Study Testing?
For cancer cells to grow, they need blood vessels to supply them with key nutrients; this process is called angiogenesis. Dalantercept and axinitib are both anti-angiogenic agents, which means they are thought to block the growth of blood vessels supporting the cancer cells.
The main goal of The DART Study is to determine whether dalantercept combined with axitinib is more effective than axitinib alone at preventing the growth and spread of renal cell carcinoma.
Acceleron Pharma aims to transform the lives of people suffering from cancer and orphan diseases through the discovery and development of more effective therapies.
Since its founding in 2004, Acceleron Pharma has distinguished itself as a world-leading developer of drugs to target various pathways of the transforming growth factor beta proteins (TGF-β). These proteins play a critical role in the growth and repair of tissues throughout the human body.
Copyright © 2017 CancerConnect. All Rights Reserved.